HIV-1 Clade A Consensus Sequences for Vaccine Antigen Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccine development faces challenges due to genetic variability of HIV strains, as existing consensus sequences are not based on recently circulating strains, leading to reduced biological relevance and increased genetic manipulation needs.
Innovation Solution
Development of new consensus sequences for HIV-1 Clade A antigens based on recently isolated strains, with methods to identify and mutate sequences to minimize genetic changes while maintaining biological relevance, using adenovirus vectors for immunogenic compositions to generate an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing consensus sequences are used for HIV-1 vaccine development, then the sequences are available and can be used immediately, but they lack biological relevance and require extensive genetic manipulation
Solution Approach 1:
The patent performs preliminary action by selecting and sequencing antigens from recently circulating HIV-1 Clade A field isolates before vaccine development. This advance preparation ensures the consensus sequences are based on current, biologically relevant strains, eliminating the need for later genetic manipulation to achieve relevance. The sequences were prepared in advance with the specific goal of creating vaccine candidates that closely match circulating strains.
Solution Approach 2:
The patent applies parameter changes by updating the source material from older, established consensus sequences to newly sequenced antigens from recent field isolates. This changes the temporal parameter (recency of strains) and genetic parameter (sequence identity to circulating viruses), resulting in consensus sequences that require minimal genetic manipulation while maintaining high biological relevance.
2Ease of manufacture
If consensus sequences are based on older strains, then the sequences are well-established and available, but they show reduced biological relevance to currently circulating viruses
Solution Approach 1:
The patent performs preliminary action by proactively sequencing and analyzing antigens from recently circulating HIV-1 Clade A field isolates before initiating vaccine development. This advance preparation ensures the consensus sequences reflect current viral diversity and biological relevance, rather than relying on outdated sequences. The preliminary sequencing work was completed to establish accurate, contemporary reference sequences.
Solution Approach 2:
The patent applies parameter changes by transitioning from older, established strain sequences to newly sequenced recent field isolates. This changes the temporal parameter (strain recency) and genetic parameter (sequence similarity to circulating viruses), resulting in consensus sequences that maintain availability while significantly improving biological relevance to current epidemics.
3Stability of the object's composition
If naturally occurring sequences with close relationship to consensus are used, then genetic stability is improved, but selection and identification processes are required
Solution Approach 1:
The patent applies the extraction principle by selecting and isolating specific antigens (Gag, Pol, Env, Nef) from recently circulating HIV-1 field isolates that exhibit high sequence identity to the consensus sequences. This extraction of closely related natural sequences eliminates the need for extensive genetic manipulation, thereby improving genetic stability while the systematic selection process ensures identification of optimal candidates.
Solution Approach 2:
The patent applies parameter changes by establishing a quantitative threshold for sequence identity (high similarity to consensus) as a selection criterion. This parameter change transforms the selection process from arbitrary choice to systematic identification based on measurable genetic distance, improving genetic stability while maintaining a manageable identification process through objective criteria.
Data Source
AI summary
The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. Advantageously, the present invention relates to HIV-1 Clade A transgenes that are derived from such sequences, and that encode either HIV-1 Clade A Gag, Pol (RT and Int), and Nef (collectively “GRIN”), HIV-1 Clade A Gag, RT, and Nef (collectively “GRN”), or HIV-1 Clade A Env. The invention also relates to vectors containing such transgenes, including adenovirus vectors containing such transgenes. The invention also relates to immunogenic compositions comprising the HIV-1 Clade A antigens, nucleotide sequences, vectors, or transgenes of the invention, and to methods of generating an immune response against HIV in a subject by administering an effective amount of such immunogenic compositions.